CN101597217B - PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes - Google Patents
PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes Download PDFInfo
- Publication number
- CN101597217B CN101597217B CN2008100168030A CN200810016803A CN101597217B CN 101597217 B CN101597217 B CN 101597217B CN 2008100168030 A CN2008100168030 A CN 2008100168030A CN 200810016803 A CN200810016803 A CN 200810016803A CN 101597217 B CN101597217 B CN 101597217B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- dimethoxy
- compound
- bromo
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a novel chemical synthesis method of PTP1B inhibitor and the application thereof in the medicine for curing type 2 diabetes, wherein the PTP1B inhibitor has a chemical structural formula as follows: wherein a group connected with 2 site, 2' site and 3 site carbon of benzene ring is bromine atom; 4,4' and the number 5, 5' carbon of the benzene ring are connected with methoxyl; and the PTP1B inhibitor has a chemical name in English: (2'-bromo-4',5'-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-methane. The compound can enhance the sensibility of insulin receptor by restricting the activity of protein tyrosine phospholipase 1B and has favorable curing effect for type 2 diabetes in insulin resistance types.
Description
Technical field
The present invention relates to biological medicine, specifically a kind of bromo cpd " (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane " and chemical total synthesis method, pharmacologically active and pharmaceutical use.This compound and verivate thereof can be used for treating insulin resistant class diabetes B as euglycemic agent.
Background technology
Mellitus (Diabetes Mellitus; DM) be a kind of chronic incretion metabolism disease; According to IDF (IDF) data in 2007, whole world maturity-onset diabetes patient number was about 2.46 hundred million, and wherein diabetes B (T2DM) patient accounts for total glycosuria patient more than 90%.By 2025, global diabetic subject's number was estimated to reach 3.8 hundred million.The medicine that is used to treat T2DM at present mainly contains biguanides, sulfourea, alpha-glucosidase inhibitor and thiazolidinediones etc., because they mostly are to illness rather than are directed against the design of cause of disease molecular target medicine, thereby has various drawbacks.Therefore, safe and effective, reasonable price of market in urgent need and the ofhypoglycemic medicine can long-term safety taken.
Insulin resistant is the key factor of T2DM morbidity; Regular Insulin is through combining with the outer α subunit of acceptor born of the same parents; β subunit intrinsic tyrosine kinase activity in the activated receptor born of the same parents; Cause the tyrosine residues autophosphorylation, thereby activate insulin receptor tyrosine kinase fully, through the phosphorylation IRS signal is handed on again.Tyrosine phosphorylation is the important step that the Regular Insulin effect realizes, being acted on the pair of opposite enzyme is that PTK and PTP regulate.The effect of PTK in the insulin signaling transmission promptly paid close attention to by people very early, but up to date, people just recognize the importance of PTP in onset diabetes gradually.
(Protein tyrosine phosphatase 1B PTP1B), is one of main member in the Protein-tyrosine-phosphatase family to PTP 1B.Human PTP1B gene is positioned at karyomit(e) 20q13.1 zone No. 2, and mouse PTP1B gene is positioned at end of chromosome H2-H3 district No. 2, and the zone at the two place is all relevant with mellitus and obesity.PTP1B plays important negative regulation effect in insulin signaling transduction path.Research confirms; Using P TP1B suppressor factor can make insulin receptor and substrate phosphorylation level thereof raise in the insulin sensitivity cell; Promote the picked-up of glucose transporter transposition and increase glucose etc., the PTP1B suppressor factor has played the effect of insulin analog and euglycemic agent.Knock out the PTP1B gene or suppress the expression of PTP1B albumen and mRNA in the body, not only can significantly improve and tried the susceptibility of mouse, and can obviously reduce patient's probability of obesity Regular Insulin with GEM 132 (ASO).Gold-stein research shows that PTP1B and LARPTP express in insulin resistant patient's the insulin target tissue increases, and the expression increase of these two kinds of PTP can be blocked the activation of insulin receptor tyrosine and the signal transduction of Regular Insulin.P387L is a kind of missense mutation of PTP1B, and Echwald etc. confirm that this gene mutation frequency is 1.4% among the diabetes B patient, and the normal control group is merely 0.5%, so think that this variation is relevant with diabetes B.Adopt the PTP1B antisense oligonucleotide to handle mellitus type mouse (ob/ob mouse); Suppressing its PTP1B expresses; During the down-regulated expression of discovery PTP1B in liver, fat and skeletal muscle, it is normal that the ob/ob mouse blood sugar recovers, and each item index relevant with carbohydrate metabolism all is tending towards normal; The experiment of Regular Insulin clamp shows that the liver and the peripheral tissues of diabetic mice strengthen insulin sensitivity.These results confirm the negative regulation effect of PTP1B in the insulin signaling transduction, and its activity increases, and possibly be an insulin resistant and an impaired paathogenic factor of insulin receptor signal take place.Therefore, seek the novel targets that small molecules PTP1B suppressor factor has become treatment T2DM.
Few to the research of PTP1B suppressor factor in the world, mainly contain following several types: (1), peptide class: the peptide class substrate and the PTP1B of phosphorous acidifying tyrosine residues (pTyr) have higher affinity, but its chemistry and biologically stable are poor; (2), naphthoquinones class Naphthnoquinone: the activity of coming inhibitory enzyme through the avtive spot of modifying PTPase; (3), thiazolidinediones Azolidinediones: the insulin sensitivity through increasing target organ improves Blood glucose control; Mainly comprise ciglitazone, troglitazone and rosiglitazone; But because serious hepatotoxicity, ciglitazone withdraws from from market; (4), Benzo [b] naphthol [2,3-d] furans and thiophenes class: with benzbromarone (PTP1B suppressor factor, IC
50=26 μ M) design synthetic series Benzo [b] naphthol [2 for lead compound; 3-d] furans and thiophenes compounds; In the mouse body, show good hypoglycemic activity; Also need overcome a lot of obstacles but will finally become the treatment diabetes medicament, like electronegativity height, permeability of cell membrane difference and selection specificity difference etc., above factor all makes the one-tenth property of medicine of these suppressor factor reduce.We have found that from marine alga a series of PTP1B of having suppress active bromo marine natural product; And in view of the above the design synthesized strong PTP1B suppress active new compound-(2 '-bromo-4 '; 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane.
Summary of the invention
The object of the invention be to provide a kind of novel PTP1B suppressor factor-" (2 '-bromo-4 '; 5 '-dimethoxy-phenyl)-(2; 3-two bromo-4,5-dimethoxy-phenyl)-methane ", this compound and verivate thereof the activity through arrestin tyrosine Phospholipid hydrolase 1B; Strengthen insulin receptor susceptibility, can be used for treating insulin resistant class diabetes B.
For realizing above-mentioned purpose, the technical scheme that the present invention adopts is following:
1, " (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane " chemical complete synthesis and structure identify
(1) (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-the chemical complete synthesis route map of methane6
Scheme 1 (a) polyphosphoric acid, 75～85 ℃, 50～70min; (b) bromine (bromine: compound 3 mol ratios=2: 1), acetate, room temperature; (c) bromine (bromine: compound 4 mol ratios=1: 1), aluminum chloride, acetate, 75～85 ℃; (d) trifluoroacetic acid, triethyl silicane, room temperature.
(2) Bis-(3,4-dimethoxy-phenyl)-chemosynthesis of methanone3 and structure identify
According to 1: 1 ratio of mol ratio veratric acid (compound 1), veratrole (compound 2) are joined in three mouthfuls of reaction flasks with polyphosphoric acid, the mass ratio of veratric acid and polyphosphoric acid is 1: 4～1: 5,75～85 ℃ of stirring reaction 50～70min; Be cooled to 60 ℃ and in 30min in reactant the mixture of ice and water of 5 times of volumes of dropwise reaction system, separate out a large amount of water-fast pink solid in the reactant this moment; After filtration dewaters, the solid that obtains is dissolved in the methylene dichloride, the mass ratio of solid and methylene dichloride is 1: 3～1: 5, washs respectively 3～5 times with isopyknic mass concentration 3% sodium hydroxide solution and zero(ppm) water successively; The anhydrous sodium sulfate drying methylene dichloride mutually after, concentrating under reduced pressure gets pink solid; Evaporated under reduced pressure gets faint yellow solid behind the petroleum ether solids three times, through Spectrum Analysis, the conclusive evidence compound be Bis-(3,4-dimethoxy-phenyl)-methanone;
This compound physico-chemical property is following: white powder, and fusing point 145.3-146.1 ℃, proton nmr spectra:
1H NMR (500MHz, CDCl
3): δ 3.92 (s, 6H), 3.94 (s, 6H), 6.88 (d, J=8.4Hz, 2H), 7.36 (dd, J=8.4,1.8Hz, 2H), 7.41 (d, J=1.8Hz, 2H); Carbon-13 nmr spectra:
13C NMR (125MHz, CDCl
3): δ 56.03 (q), 109.79 (d), 112.39 (d), 124.69 (d), 130.82 (s), 148.9 (s), 152.61 (s), 194.35 (s).
(3) Bis-(2-bromo-4,5-dimethoxy-phenyl)-chemosynthesis of methanone4 and structure identify
To react preparation in (2) compound 3Bis-(3,4-dimethoxy-phenyl)-methanone adds in three mouthfuls of reaction flasks with acetate (mass ratio is 1: 7～1: 9), stir fast under the room temperature solid is dissolved; Bromine is added to dilution in the acetate (volume ratio 1: 2), and compd B is-(3,4-dimethoxy-phenyl)-methanone: bromine mol ratio=1: 2, drop to fast in the reaction flask under the room temperature, dropwise in the 20min; After bromine dropwises, stir under the room temperature and continue have light-yellow precipitate to separate out behind the reaction 1h, TLC detection reaction terminal point, stopped reaction after raw material point disappears; Reaction solution is poured the separating funnel that fills saturated aqueous common salt into, adds dichloromethane extraction 3～5 times, merges organic phase; Anhydrous sodium sulfate drying gets brown solid behind the concentrating under reduced pressure; Acetone repetitive scrubbing solid, evaporated under reduced pressure gets micro-yellow powder, through Spectrum Analysis, the conclusive evidence compound be Bis-(2-bromo-4,5-dimethoxy-phenyl)-methanone;
This compound physico-chemical property is following: pale yellow powder, and fusing point 172.5-173.2 ℃, proton nmr spectra:
1H NMR (500MHz, CDCl
3): δ 3.87 (s, 6H), 3.94 (s, 6H), 7.05 (s, 4H); Carbon-13 nmr spectra:
13C NMR (125MHz, CDCl
3): δ 56.26 (q), 56.33 (q), 113.22 (s), 114.0 (d), 116.36 (d), 131.76 (s), 148.40 (s), 152.01 (s), 194.26 (s).
(4) (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-chemosynthesis of methanone5 and structure identify
To react the compound 4Bis-(2-bromo-4 of preparation in (3); 5-dimethoxy-phenyl)-methanone and acetate (mass ratio is 1: 18～1: 22) adds in the reaction flask, is warming up to 40～50 ℃ and adds aluminum chlorides (aluminum chloride: the quality of acetic acid ratio is 1: 10～1: 15); Stirring reaction 30min postcooling is to room temperature; Bromine is added to dilution in the acetate (volume ratio 1: 17); Compd B is-(2-bromo-4,5-dimethoxy-phenyl)-methanone: drop in the reaction flask under the bromine mol ratio=1: 1, room temperature; Dropwise in the 1h; Slowly be warming up to 80 ℃ of backflows then, TLC detection reaction terminal point, stopped reaction after raw material point disappears; Reaction solution is poured the separating funnel that fills volume by volume concentration 3% hydrochloric acid soln into, adds dichloromethane extraction 3～5 times, merges organic phase, gets brown solid after the evaporated under reduced pressure; Adopt silica gel column chromatography (sherwood oil: ETHYLE ACETATE volume ratio=6: 1 be an eluent) purifying, white powder, pass through Spectrum Analysis; The conclusive evidence compound be (2 '-Bromo-4 '; 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-methanone;
This compound physico-chemical property is following: white powder, and fusing point 160.8-161 ℃, proton nmr spectra:
1H NMR (500MHz, CDCl
3): δ 3.87 (s, 6H), 3.92 (s, 3H), 3.94 (s, 3H), 6.97 (s, 1H), 6.87 (s, 1H), 7.07 (s, 1H), 7.16 (s, 1H); Carbon-13 nmr spectra:
13C NMR (125MHz, CDCl
3): δ 56.35 (q), 56.39 (q), 56.44 (q), 60.76 (q), 113.08 (s), 114.32 (s); 114.47 (d), 114.67 (s), 116.85 (d), 123.05 (d), 130.04 (s), 137.84 (s); 148.44 (s), 149.69 (s), 152.69 (s), 152.74 (s), 193.61 (s).
(5) (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-chemosynthesis of methane6 and structure identify
To react preparation in (4) compound 5 (2 '-Bromo-4 '; 5 '-dimethoxy-phenyl)-(2; 3-dibromo-4,5-dimethoxy-phenyl)-methanone and trifluoroacetic acid (mass ratio 1: 10～1: 12) add in three mouthfuls of reaction flasks, and agitation condition adds triethyl silicane (triethyl silicane and trifluoroacetic acid volume ratio are 1: 10) down fast;, stirring reaction under the room temperature; TLC detection reaction terminal point adds the zero(ppm) water termination reaction after raw material point disappears; Reaction solution merges organic phase, anhydrous sodium sulfate drying with dichloromethane extraction 3～5 times; Get pale solid after the evaporated under reduced pressure; Through Spectrum Analysis, the conclusive evidence compound be (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2; 3-dibromo-4,5-dimethoxy-phenyl)-methane.
This compound physico-chemical property is following: white powder, and fusing point 113.3-114.7 ℃, proton nmr spectra:
1H NMR (500MHz, CDCl
3): δ 3.71 (s ,-OCH
3), 3.77 (s ,-OCH
3), 3.83 (s ,-OCH
3), 3.88 (s ,-OCH
3), 4.15 (s ,-CH
2), 6.54 (s, 1H), 6.62 (s, 1H), 7.07 (s, 1H); Carbon-13 nmr spectra:
13C NMR (125MHz, CDCl
3): δ 43.13 (t) 56.16 (q), 56.17 (q), 56.20 (q), 60.5 (q), 113.32 (d), 113.68 (d); 114.86 (s), 115.76 (d), 117.71 (s), 121.91 (s), 130.61 (s); 136.71 (s), 146.35 (s), 148.58 (s), 148.73 (s), 152.53 (s).
2, protein-tyrosine Phospholipid hydrolase 1B suppresses determination of activity
Adopt molecular biology method; Make up the human PTP1B engineering bacteria of hGST-PTP1B-BL21E.Coli of recombination; With GST affinity chromatography column purification hGST-PTP1B protein; The polypeptide para-Nitrophenyl Phosphate (pNPP) that utilization contains phosphoric acid is fallen a product pNP behind the phosphoric acid has absorption peak at wavelength 405nm place principle by the PTP1B enzymolysis; The scale that generates pNP with PTP1B effect back show that the PTP1B enzymic activity changes and compound to the inhibition situation of enzymic activity, computerized compound PTP1B enzyme activity inhibiting rate.
Said compound is the new compound with PTP1B enzyme inhibition activity; Can strengthen insulin receptor susceptibility through negative regulation insulin signaling transduction path, the Regular Insulin physiological function is normally brought into play; And then regulating and controlling blood sugar, reach therapeutic efficiency to insulin resistant class diabetes B; Chemical equivalence things such as acceptable salt, ester or ether can mix with pharmaceutically acceptable pharmaceutical carrier and can be made into tablet, capsule, oral liquid, granule, pill or the injection of treatment to insulin resistant class diabetes B on its compound itself and the pharmacology.
The present invention has following advantage:
Said target compound is the brand new compound with remarkable PTP1B enzyme inhibition activity, is the treatment new drug of insulin resistant class diabetes B; The present invention has carried out chemical complete synthesis to it, the starting raw material that selection cheaply is easy to get reduces reaction cost, realized the high yield of target compound, synthetic cheaply, and technological operation is simple, has good industrialization prospect of production.
Embodiment
Embodiment 1 " (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane " chemical complete synthesis and structure identify
(1) Bis-(3,4-dimethoxy-phenyl)-chemosynthesis of methanone3 and structure identify
According to 1: 1 ratio of mol ratio 22.08g (120mmol) veratric acid (compound 1), 16.92g (120mmol) veratrole (compound 2) are joined in three mouthfuls of reaction flasks of 250ml 80 ℃ of stirring reaction 1h with the 100g polyphosphoric acid; Be cooled to 60 ℃ and in 30min, in reactant, drip the 250ml frozen water, separate out a large amount of water-fast pink solid in the reactant this moment; After filtration dewaters, the solid that obtains is dissolved in the 100ml methylene dichloride, uses isopyknic 3% sodium hydroxide solution and distilled water wash three times successively; The anhydrous sodium sulfate drying methylene dichloride mutually after, concentrating under reduced pressure gets pink solid; Evaporated under reduced pressure gets faint yellow solid 3 (30.68g, productive rate 85%) behind the petroleum ether solids three times, through Spectrum Analysis, the conclusive evidence compound be Bis-(3,4-dimethoxy-phenyl)-methanone.
(2) Bis-(2-bromo-4,5-dimethoxy-phenyl)-chemosynthesis of methanone4 and structure identify
(15.1g 50mmol) adds in three mouthfuls of reaction flasks of 250ml with 120ml acetate, stirs fast under the room temperature solid is dissolved will to react the compound 3 for preparing in (1); The 5.3ml bromine added in the 10ml acetate dilute, drop to fast under the room temperature in three mouthfuls of reaction flasks, dropwise in the 20min; After bromine dropwises, stir under the room temperature and continue have light-yellow precipitate to separate out behind the reaction 1h, TLC detection reaction terminal point, stopped reaction after raw material point disappears.Reaction solution is poured the separating funnel that fills the 120ml saturated aqueous common salt into, adds methylene dichloride (each 100ml) extraction three times, merges organic phase; Anhydrous sodium sulfate drying gets brown solid behind the concentrating under reduced pressure; Washing with acetone solid 4 to 6 times, evaporated under reduced pressure get micro-yellow powder 4 (18.87g, productive rate 82%), through Spectrum Analysis, the conclusive evidence compound be Bis-(2-bromo-4,5-dimethoxy-phenyl)-methanone.
(3) (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-chemosynthesis of methanone5 and structure identify
(4.6g 10mmol) adds in three mouthfuls of reaction flasks of 250ml with 100ml acetate, is warming up to 45 ℃ and adds the 1.0g aluminum chlorides will to react the compound 4 for preparing in (2); Stirring reaction 30min postcooling is to room temperature; The 0.6ml bromine added in the 10ml acetate dilute, drop under the room temperature in three mouthfuls of reaction flasks, dropwise in the 1h, slowly be warming up to 80 ℃ of backflows then, TLC detection reaction terminal point, the raw material point back stopped reaction that disappears.Reaction solution is poured into and is filled the separating funnel that the 150ml volume by volume concentration is 3% hydrochloric acid soln, adds methylene dichloride (each 100ml) extraction three times, merges organic phase, gets brown solid after the evaporated under reduced pressure; Adopt silica gel column chromatography (sherwood oil: ETHYLE ACETATE volume ratio=6: 1 is an eluent) purifying; Get white powder 5 (2.21g, productive rate are 41%), through Spectrum Analysis; The conclusive evidence compound be (2 '-Bromo-4 '; 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-methanone.
(4) (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-chemosynthesis of methane6 and structure identify
(2.7g 5mmol) adds in three mouthfuls of reaction flasks of 250ml with the 20ml trifluoroacetic acid, and quick agitation condition is adding 2ml triethyl silicane down, stirring reaction under the room temperature will to react the compound 5 for preparing in (3); TLC detection reaction terminal point adds 50ml zero(ppm) water termination reaction after raw material point disappears.Reaction solution merges organic phase, anhydrous sodium sulfate drying with methylene dichloride (each 50ml) extraction three times; Get pale solid 6 (1.83g, productive rate 70%) after the evaporated under reduced pressure, through Spectrum Analysis; The conclusive evidence compound be (2 '-Bromo-4 '; 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-methane.
Reaction overall yield=85% * 82% * 41% * 70%=20.0%
Embodiment 2 protein-tyrosine Phospholipid hydrolase 1B suppress determination of activity
With testing compound " (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4; 5-dimethoxy-phenyl)-methane " be mixed with the need testing solution of different concns with DMSO, get survey live body system (50mM Tris-HCl, PH6.5 that 2 μ L need testing solutions join standard respectively; 2mM pNPP, 2%DMSO, 30 nM hGST-PTP1B); Negative control: DMSO, positive control: sodium vanadate, temperature of reaction are 30 ℃; The dynamic measurement wavelength is the photoabsorption at 405nm place, and time 3min is by following formula computerized compound PTP1B enzyme activity inhibiting rate.Inhibiting rate=(experimental group A value-negative control group A value)/(control group A value-negative control group A) * 100%, the result sees table 1.
Table 1 protein-tyrosine Phospholipid hydrolase 1B inhibiting rate (%)
Table?1?Inhibitory?Ratio (％)of?PTP1B
Test-results shows: 6 pairs of protein tyrosine phosphatase esterases of compound 1B shows significant inhibitory effect, has good anti-diabetes B potential applicability in clinical practice.
Claims (5)
1. PTP1B suppressor factor is characterized in that: said PTP1B suppressor factor be compound (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane, structural formula is following:
Wherein 2,2 of phenyl ring ' be bromine atoms with 3 groups that carbon was connected; 4,4 ', 5 and 5 ' position carbon and methoxyl group join; Chemical name Chinese is: (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane; English is: (2 '-Bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-dibromo-4,5-dimethoxy-phenyl)-methane.
2. said suppressor factor chemical synthesis process of claim 1 is characterized in that: the synthetic route of described compound is:
Formula 1 (a) polyphosphoric acid, 75～85 ℃, 50～70min; (b) bromine, bromine: compound 3 mol ratios=2: 1, acetate, room temperature; (c) bromine, bromine: compound 4 mol ratios=1: 1, aluminum chloride, acetate, 75～85 ℃; (d) trifluoroacetic acid, triethyl silicane, room temperature.
3. according to the said chemical synthesis process of claim 2, it is characterized in that: it is following that said suppressor factor specifically prepares process,
(1) according to 1: 1 ratio of mol ratio veratric acid, veratrole and polyphosphoric acid are joined in the container bottle, the mass ratio of veratric acid and polyphosphoric acid is 1: 4～1: 5,75～85 ℃ of stirring reaction 50～70min; Be cooled to 60 ℃ and in 30min in reactant the mixture of ice and water of 5 times of volumes of dropwise reaction system, separate out a large amount of water-fast pink solid in the reactant this moment; After filtration dewaters, the solid that obtains is dissolved in the methylene dichloride, the mass ratio of solid and methylene dichloride is 1: 3～1: 5, washs respectively 3～5 times with isopyknic mass concentration 3% sodium hydroxide solution and zero(ppm) water successively; The anhydrous sodium sulfate drying methylene dichloride mutually after, concentrating under reduced pressure gets pink solid; Evaporated under reduced pressure gets faint yellow solid behind the petroleum ether solids three times, and through Spectrum Analysis, the conclusive evidence compound be pair-(3,4-dimethoxy-phenyl)-ketone;
(2) will react compound of preparation in (1) two-(3,4-dimethoxy-phenyl)-ketone adds in the reaction flask with acetate, stirs fast under the room temperature solid is dissolved, their mass ratios are 1: 7～1: 9; Bromine added in the acetate dilute, their volume ratios 1: 2, compound is two-(3,4-dimethoxy-phenyl)-ketone: bromine mol ratio=1: 2, drop to fast in the reaction flask under the room temperature, dropwise in the 20min; After bromine dropwises, stir under the room temperature and continue have light-yellow precipitate to separate out behind the reaction 1h, TLC detection reaction terminal point, stopped reaction after raw material point disappears; Reaction solution is poured the separating funnel that fills saturated aqueous common salt into, adds dichloromethane extraction 3～5 times, merges organic phase; Anhydrous sodium sulfate drying gets brown solid behind the concentrating under reduced pressure; Acetone repetitive scrubbing solid, evaporated under reduced pressure gets micro-yellow powder, and through Spectrum Analysis, the conclusive evidence compound is two-(2-bromo-4,5-dimethoxy-phenyl)-ketone;
(3) will react compound of preparation in (2) two-(2-bromo-4; 5-dimethoxy-phenyl)-ketone and acetate adds in the reaction flask; Their mass ratios are 1: 18～1: 22, are warming up to 40～50 ℃ and add aluminum chloride, and aluminum chloride: the quality of acetic acid ratio is 1: 10～1: 15; Stirring reaction 30min postcooling is to room temperature; Bromine added in the acetate dilute, their volume ratios 1: 17, compound is two-(2-bromo-4; 5-dimethoxy-phenyl)-and ketone: bromine mol ratio=1: 1; Drop in the reaction flask under the room temperature, dropwise in the 1h, slowly be warming up to 80 ℃ of backflows then; TLC detection reaction terminal point, stopped reaction after raw material point disappears; Reaction solution is poured the separating funnel that fills volume by volume concentration 3% hydrochloric acid soln into, adds dichloromethane extraction 3～5 times, merges organic phase, gets brown solid after the evaporated under reduced pressure; Adopt silica gel chromatography, sherwood oil: ETHYLE ACETATE volume ratio=6: 1 be an eluent, white powder, through Spectrum Analysis, the conclusive evidence compound be (2 '-bromo-4 ', 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-ketone;
(4) will react preparation in (3) compound (2 '-bromo-4 '; 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-ketone and trifluoroacetic acid add in the reaction flask; Their mass ratio 1: 10～1: 12; Agitation condition adds triethyl silicane down fast, and triethyl silicane and trifluoroacetic acid volume ratio are 1: 10, stirring reaction under the room temperature; TLC detection reaction terminal point adds the zero(ppm) water termination reaction after raw material point disappears; Reaction solution merges organic phase, anhydrous sodium sulfate drying with dichloromethane extraction 3～5 times; After the evaporated under reduced pressure pale solid, through Spectrum Analysis, the conclusive evidence compound be (2 '-bromo-4 '; 5 '-dimethoxy-phenyl)-(2,3-two bromo-4,5-dimethoxy-phenyl)-methane.
4. the application of the said suppressor factor of claim 1 in preparation treatment diabetes B medicine; The said compound of claim 1 is the compound with PTP1B enzyme inhibition activity; Can strengthen insulin receptor susceptibility through negative regulation insulin signaling transduction path, the Regular Insulin physiological function is normally brought into play; And then regulating and controlling blood sugar, reach therapeutic efficiency to insulin resistant class diabetes B.
5. according to the application of the said suppressor factor of claim 1 in preparation treatment diabetes B medicine; It is characterized in that: the said compound of claim 1 has PTP1B and suppresses active, and acceptable salt and pharmaceutically acceptable pharmaceutical carrier are mixed and made into tablet, capsule, oral liquid, granule, pill or the injection of treatment to insulin resistant class diabetes B on its compound itself and the pharmacology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100168030A CN101597217B (en) | 2008-06-06 | 2008-06-06 | PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100168030A CN101597217B (en) | 2008-06-06 | 2008-06-06 | PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101597217A CN101597217A (en) | 2009-12-09 |
| CN101597217B true CN101597217B (en) | 2012-07-04 |
Family
ID=41418841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100168030A Expired - Fee Related CN101597217B (en) | 2008-06-06 | 2008-06-06 | PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101597217B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100685B (en) * | 2009-12-18 | 2012-12-26 | 中国科学院海洋研究所 | PTP1B inhibitor and synthetic method and application thereof |
| CN102020541B (en) * | 2010-04-13 | 2012-09-12 | 中国科学院海洋研究所 | Protein tyrosine phosphatase 1B (PTP1B) inhibitor as well as chemical synthesis method and application thereof |
| CN102018688B (en) * | 2010-08-06 | 2012-10-10 | 中国科学院海洋研究所 | PTP1B inhibitor and synthesis and application thereof in preparation of medicine used for treating type II diabetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853618A (en) * | 2005-04-20 | 2006-11-01 | 中国科学院海洋研究所 | Use of bromphenol compound in protein-tyrosine phosphonatease inhibitor |
-
2008
- 2008-06-06 CN CN2008100168030A patent/CN101597217B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853618A (en) * | 2005-04-20 | 2006-11-01 | 中国科学院海洋研究所 | Use of bromphenol compound in protein-tyrosine phosphonatease inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101597217A (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101597213B (en) | Chemical synthesis method of bromphenol PTP1B inhibitor | |
| CN101597216B (en) | Brominated PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes | |
| Borgo et al. | Protein kinase CK2 inhibition as a pharmacological strategy | |
| CN101597217B (en) | PTP1B inhibitor as well as synthesis method and application thereof in preparation of medicine for curing type 2 diabetes | |
| CN114315848B (en) | Small molecule inhibitors of insulin-like growth factor-1 receptor and uses thereof | |
| Jiang et al. | Discovery of novel bromophenol 3, 4-dibromo-5-(2-bromo-3, 4-dihydroxy-6-(isobutoxymethyl) benzyl) benzene-1, 2-diol as protein tyrosine phosphatase 1B inhibitor and its anti-diabetic properties in C57BL/KsJ-db/db mice | |
| CN107216283B (en) | A kind of beta-elemene derivatives and its preparation method and application containing dihydropyridine structure | |
| CN102020545B (en) | PTP1B inhibitor, synthesis and application thereof | |
| CN102100685B (en) | PTP1B inhibitor and synthetic method and application thereof | |
| CN102018688B (en) | PTP1B inhibitor and synthesis and application thereof in preparation of medicine used for treating type II diabetes | |
| CN102020546B (en) | PTP1B inhibitor and preparation and application in preparing drug for treating type 2 diabetes mellitus thereof | |
| CN102020540B (en) | Three protein tyrosine phosphatase 1B (PTP1B) inhibitors and synthesis and application thereof | |
| CN102101825A (en) | PTP1B (Protein Tyrosine Phosphatase 1B) inhibitor, and synthesis and application thereof | |
| CN102020539B (en) | PTP1B (Protein Tyrosine Phosphatase 1B) inhibitor, synthesis and application thereof in preparation of drugs for treating type 2 diabetes mellitus | |
| CN102020547B (en) | PTP1B (Protein Tyrosine Phosphatase 1B) inhibitor as well as chemical synthesis method and application thereof | |
| CN102020537B (en) | Protein tyrosine phosphatase 1B (PTP1B) inhibitor, and synthesis and application thereof | |
| CN103450163A (en) | Indazole compounds, preparation method, and pharmaceutical applications thereof | |
| CN102020541B (en) | Protein tyrosine phosphatase 1B (PTP1B) inhibitor as well as chemical synthesis method and application thereof | |
| CN102020538B (en) | PTP1B (Protein Tyrosine Phosphatase 1B) inhibitor as well as synthesis method and application thereof to preparation of type 2 diabetes medicament | |
| CN114671751B (en) | O-hydroxyphenylketone compound and preparation method and application thereof | |
| CN102018692B (en) | PTP1B inhibitors and synthesis thereof, and application of PTP1B inhibitors in preparation of medicines for treating type 2 diabetes | |
| CN101591357A (en) | One group is suppressed the kinase whose phosphate/phosphate ester compounds of BCR-ABL | |
| CN106008557A (en) | Application of 3,6-diaryl-[1,2,4] triazolo[3,4-b][1,3,4] thiadiazole compound as tumor cell proliferation inhibitor | |
| CN103910727B (en) | STAT3-Hif1 alpha signal pathway inhibitor and the application in antitumor thereof | |
| CN112920118B (en) | Genipin amino acid derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20170606 |